title: Contribution of Ras farnesyl transferase, MAP kinase and cytochrome P-450 metabolites to endothelin-1 induced hypertension.
abstract: Endothelin 1 (ET-1) is vasoactive peptide that acts via ET-A receptors coupling inducing vascular smooth muscle cell proliferation and contraction. ET-1 is involved in the development and maintenance of hypertension. Aim of this study was to determine the contribution of Ras farnesyl transferase, mitogen activated protein kinase (MAP kinase) and cytochrome P¬450 (CYP450) metabolites to ET-1 induced hypertension. ET-1 (5 pmol/kg per minute) was chronically infused into to the jugular vein by use of mini-osmotic pump for 9 days in male Sprague-Dawley rats. Mean arterial blood pressure (MABP) in ET-1-treated rats was 154±2 mm Hg (hypertensive rats) compared with 98±3 mm Hg in control (normotensive) rats. Infusion of Ras farnesyl transferase inhibitor FPTIII (138 ng/min), MAP kinase inhibitor PD-98059 (694 ng/min) and CYP450 inhibitor 17-ODYA (189 ng/min) significantly attenuated MABP to 115±2.5 mm Hg, 109±3 mm Hg and 118±1.5 mm Hg, respectively. These results suggest that CYP-450 metabolites and Ras/MAP kinase pathway contribute to the development of ET-1 induced hypertension. Further investigation has to be done to confirm whether activation of RAS/MAP kinase pathway by arachidonic acid metabolites plays an important role in the development of ET-1 induced hypertension.
authors: Department of Physiology, University of Tuzla, Faculty of Medicine, Univerzitetska, Tuzla, Bosnia and Herzegovina. farid.ljuca@untz.ba
authors: Farid
authors: F
authors: Ljuca
authors: Gorazd
authors: G
authors: Drevenšek
authors: Enver
authors: E
authors: Zerem
references: Hypertension. 2000 Oct;36(4):604-9
references: 11040243
references: Hypertension. 2003 Oct;42(4):806-10
references: 12874096
references: Pharmacol Rev. 1994 Sep;46(3):325-415
references: 7831383
references: Annu Rev Pharmacol Toxicol. 1981;21:479-509
references: 7016014
references: Hypertension. 1990 Jun;15(6 Pt 2):729-33
references: 2190924
references: Trends Cardiovasc Med. 1996 Jan;6(1):4-10
references: 21232268
references: Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12701-6
references: 9770549
references: Hypertension. 1998 Jan;31(1 Pt 2):242-7
references: 9453310
references: Eur J Pharmacol. 1999 Jun 30;375(1-3):133-8
references: 10443571
references: Hypertension. 2002 Feb;39(2 Pt 2):704-9
references: 11882635
references: Hypertension. 2000 Jan;35(1 Pt 2):457-63
references: 10642341
references: Biochem Pharmacol. 2002 Aug 1;64(3):425-31
references: 12147293
references: J Biol Chem. 1996 Nov 22;271(47):30149-57
references: 8939965
references: Bosn J Basic Med Sci. 2010 Aug;10(3):223-6
references: 20846129